Corcept Therapeutics Incorporated.
Head Quarters
149 Commonwealth Drive USWebsite
http://www.corcept.comIndustry
PharmaceuticalsOtherEmployees
103Exchange
NASDAQCorcept Therapeutics, Inc. engages in the development of drugs for the treatment of severe psychiatric, neurological, and metabolic disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff On May 13, 1998 by and is headquartered in Menlo Park, CA.
Key statistics
| Margins | Stock |
|---|---|
| Revenue per Employee | $0.00 |
| Current Ratio | 2 |
| Gross Margin (%) | 0.98% |
| Net Margin (%) | 0.04% |
| Returns | Stock |
| Sales | $92.00M |
| Sales Growth (% qtr vs. yr ago) | 0.00% |
| Net Income | $9.00M |
| NI Growth (% qtr vs. yr ago) | 0.00% |
| Price/Sales | 134.76 |
| EPS | $0.00 |